To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

SI-generated grade · five published checks · not individually reviewed by a person · methodology

This bill is a routine administrative transparency measure within the FDA's existing statutory authority over drug approval. It does not expand federal power beyond the enumerated interstate commerce authority, does not infringe any constitutional right, and does not centralize decision-making beyond the current regulatory framework. It imposes no new burdens on individuals or states and fully respects due process and property rights.

• ✓ Passes · Enumerated powers
  The bill operates within the FDA's established authority to regulate interstate commerce in drugs under Article I, Section 8, Clause 3 (Commerce Clause). Requiring the FDA to provide additional information to generic drug applicants is a minor procedural addition to an existing federal regulatory scheme that has long been upheld as a valid exercise of the commerce power. It does not create new reg…
• ✓ Passes · Bill of Rights
  The bill does not implicate any provision of the Bill of Rights. It does not restrict speech, religion, assembly, press, petition, arms, quartering, search and seizure, self-incrimination, due process, takings, trial rights, or cruel and unusual punishment. It is a purely administrative disclosure requirement directed at the FDA, not at individuals or their protected activities.
• ✓ Passes · Individual sovereignty
  The bill imposes no restriction on individual liberty, property, speech, labor, or belief. It only requires the FDA to provide information to drug applicants, which is a benefit to those applicants. It does not compel any individual to act or refrain from acting. The burden of any government action is on the government, and here the government is merely being asked to be more transparent in its ex…
• ✓ Passes · Decentralization
  The bill does not consolidate decision-making at a higher level of government. The FDA already has exclusive authority over generic drug approvals, and this bill merely adds a transparency requirement within that existing federal framework. It does not shift authority from individuals, local communities, or states to the federal government; it only refines how the federal government exercises its …
• ✓ Passes · Due process and takings
  The bill enhances procedural fairness by requiring the FDA to explain its determinations regarding generic drug sameness, which gives applicants clearer notice of the basis for decisions. It does not deprive anyone of property without due process; rather, it provides additional information that could help applicants understand and potentially challenge adverse decisions. There is no taking of priv…

Sources: Congress.gov: HR 1843 summary